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Abstract A region 2 kb upstream of exon 1 of the P2X7 gene
was sequenced using DNA from nine healthy individuals who
exhibited three di¡erent ATP response phenotypes (i.e. high,
low and interferon gamma-inducible). Five single nucleotide
polymorphisms were identi¢ed within the nine donor promoter
sequences but none were associated with a speci¢c ATP re-
sponse phenotype. A P2X7 loss of function polymorphism
(1513 in exon 13) was also screened for within donor DNA
but no response associations were identi¢ed. ATP response phe-
notype was positively associated with P2X7 receptor expression,
as assessed by £ow cytometry, but not with any identi¢ed re-
ceptor or promoter gene polymorphisms.
- 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
We have previously characterised a P2X7-purinergic recep-
tor-mediated pathway through which infected human macro-
phages can be signalled by exposure to extracellular ATP in
vitro to kill both virulent and avirulent mycobacterial species
rapidly [1^3]. This was shown to be a macrophage-mediated
process, as ATP had no mycobactericidal activity within cell-
free cultures. However, individual healthy cell donors were
found to display marked heterogeneity in response to ATP
in terms of the susceptibility of their macrophages to ATP-
mediated cell death and killing of intracellular mycobacteria
[2].
Only approximately 10% of individuals infected with My-
cobacterium tuberculosis actually go on to develop clinical
tuberculosis (TB) [4]. A similar percentage of healthy donors
were found to exhibit a low or non-ATP response phenotype
[2]. Moreover, cells from non-ATP responder individuals also
failed to kill intracellular mycobacteria following ATP stimu-
lation whereas cells from ATP responders e⁄ciently killed 50^
70% of such bacteria within 6 h [2]. As multiple genetic in£u-
ences are thought to a¡ect human susceptibility to TB it was
postulated that heterogeneity in ATP/P2X7 responsiveness
might prove to be an additional genetic factor in£uencing
host immunity to infection with M. tuberculosis.
A single nucleotide polymorphism (SNP) at position 1513
in exon 13 of the P2X7 gene was recently reported by Gu et al.
to cause a total loss of receptor function when inherited as a
homozygous mutation and resulted in a 50% reduction in
receptor activity as a heterozygous mutation [5]. However
this polymorphism was not found to account for all the
non-ATP responsive donors identi¢ed in their study, suggest-
ing that other factors may also be involved in regulating ATP
response phenotype [5]. The 1513 SNP was also not reported
to reduce P2X7 receptor expression on a¡ected cells [5]. This
was of interest as our laboratory has observed that the ATP
response phenotype of cells derived from healthy human do-
nors is positively associated with P2X7 receptor expression
(Stober et al., submitted for publication). The heterogeneity
in donor macrophage responsiveness to ATP is therefore pre-
dicted to be associated with genetic factors regulating P2X7
expression rather than receptor function.
To investigate this hypothesis, a search was undertaken for
polymorphisms in the putative promoter region of the P2X7
gene 2 kb upstream of exon 1 of the published P2RX7 se-
quence within the DNA of macrophages isolated from nine
healthy cell donors. The donors were individuals who had
previously been characterised by our laboratory as exhibiting
either a high, low or interferon gamma (IFNQ)-inducible ATP
responder phenotype [6].
2. Materials and methods
2.1. Cell donors
Nine healthy volunteers were recruited as blood donors to obtain
7-day cultured monocyte-derived macrophages, as previously de-
scribed [2]. These nine individuals had been identi¢ed as exhibiting
either a high responder phenotype (i.e. those exhibiting a high re-
sponse to ATP with or without IFNQ pre-activation), a low responder
phenotype (i.e. those showing little response to ATP in the presence or
absence of IFNQ), or an IFNQ-inducible responder phenotype (i.e.
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those showing a positive response to ATP which was markedly in-
creased on pre-activation with IFNQ) [6]. The study cohort then com-
prised of three donors of each of the three described ATP response
phenotypes.
2.2. 51Chromium release assay
51Cr release assays were performed to con¢rm donor ATP response
phenotype as described in [2].
2.3. Flow cytometry
Flow cytometry staining (FACS) was performed on 7-day cultured
monocyte-derived macrophages from the nine cell donors examined.
Aliquots of cells (5U105^1U106) were pelleted at 400Ug for 4 min
and labelled with either an IgG2a isotype control antibody (Dako A/S,
Denmark) (¢nal 1:100 dilution) or an anti-human P2X7 receptor anti-
body L4 (Glaxo Wellcome, Stevenage, UK) (¢nal 1:50 dilution) and
incubated for 30 min. The cells were then washed twice at 400Ug for
4 min in 1 ml of phosphate-bu¡ered saline (PBS)+1% normal goat
serum and then resuspended in a secondary antibody (anti-mouse Ig
FabP 2 FITC conjugate) (Amrad Operations, Australia) (¢nal 1:100
dilution) and incubated for 30 min on ice in the dark. The cells were
then washed one time with cold PBS+1% normal goat serum, and
resuspended in 200 ul of FACS ¢xative (4% paraformaldehyde in
PBS, pH 7.4), and stored at 2^8‡C in the dark until analysed using
a Becton Dickenson (FACS 440) £ow cytometer.
2.4. DNA isolation
DNA was isolated from the blood of nine healthy volunteer donors
using a Nucleon BACC2 kit (Tepnel). The DNA was then dissolved in
sterile distilled water and used at a ¢nal concentration of 10 ng/Wl.
2.5. Polymerase chain reaction (PCR) ampli¢cation of products for
sequencing
2.5.1. Promoter. The P2RX7 sequence was obtained from Gen-
Bank (accession number Y12851). The promoter region was assumed
to be within a 2-kb sequence upstream of P2RX7 exon 1. This 2-kb
region was split into ¢ve fragments for sequencing.
Fragment 1: forward (5P-CCT GCC TAT ATG CAA CTG AG-3P),
reverse (5P-CAG GAA ACA GCT ATG ACC GAT ACA TGT CAA
ATG TGT TC-3P); fragment 2: forward (5P-GCC TGG AAG ATT
TAA GTC ATC-3P), reverse (5P-CAG GAA ACA GCT ATG ACC
CTC TGA GTT ACT CTC CAC C-3P) ; fragment 3: forward (5P-
ACC TAA CTT TGT TGG ACT GC-3P), reverse (5P-CAG GAA
ACA GCT ATG ACC AGC CTT GCA AAT GTC ACA AG-3P) ;
fragment 4: forward (5P-ACC TAA CTT TGT TGG ACT GC-3P),
reverse (5P-CAG GAA ACA GCT ATG ACC ATC ACT GCA GCT
GCA GCA GG-3P); fragment 5: forward (5P-GCAGGCCAGG-
GAGTCA-3P), reverse (5P-ATCAGATTTGCAGGGGTAGG-3P).
Primers were used at a ¢nal concentration of 200 nM. PCR con-
ditions were as follows: fragments 1 and 2 contained 2.0 mM MgCl2,
KCl bu¡er (Applied Biosystems) (resulting in ¢nal concentrations of
10 mM Tris (pH 8.3) and 50 mM KCl), 0.025 U/Wl Amplitaq Gold
(Perkin-Elmer), 0.2 mM dNTPs. Cycling conditions were 95‡C for 14
min, 38 cycles of 94‡C for 15 s, 56‡C for 30 s and 72‡C for 90 s
followed by a ¢nal extension of 2 min at 72‡C, using a PTC225
thermal cycler (MJ Research). Fragment 3 contained 2.5 mM MgCl2,
KCl bu¡er, 0.05 U/ml Amplitaq Gold (Perkin-Elmer), 0.02 mM
dNTPs. Fragment 4 contained 1.5 mM MgCl2, KCl bu¡er, 0.05 U/
ml Amplitaq Gold (Perkin-Elmer), 0.2 mM dNTPs. Cycling condi-
tions were 95‡C for 14 min, 38 cycles of 94‡C for 15 s, 56‡C for 30 s
and 72‡C for 120 s followed by a ¢nal extension of 2 min at 72‡C.
Fragment 5 contained 1.5 mM MgCl2, KCl bu¡er, 0.05 U/ml Ampli-
taq Gold (Perkin-Elmer), 0.2 mM dNTPs. Cycling conditions were
95‡C for 14 min, 38 cycles of 94‡C for 15 s, 58‡C for 30 s and
72‡C for 90 s followed by a ¢nal extension of 2 min at 72‡C. The
PCR product sizes generated were 467 bp, 445 bp, 395 bp, 460 bp and
859 bp respectively for each fragment. PCR products were separated
by gel electrophoresis using a 1.5% agarose gel. The product was cut
out from the gel over low intensity ultraviolet (UV) light and ex-
tracted using the Qiaquick gel extraction kit (Qiagen).
2.5.2. 1513. Forward primer: 5P- AGACCTGCGATGGACTT-
CACAG-3P ; reverse primer: 5P-GCCAGGTGGCGTAGCAC-3P.
The PCR mix contained 1.0 mM MgCl2, KCl bu¡er, 200 nM of
each primer, 0.025 U/Wl Amplitaq Gold (Perkin-Elmer), 0.2 mM
dNTPs. Cycling conditions were 95‡C for 14 min, 38 cycles of 94‡C
for 15 s, 61‡C for 30 s and 72‡C for 60 s followed by a ¢nal extension
of 2 min at 72‡C, to generate a 379-bp product. The product was cut
from the gel over low intensity UV light and extracted using the
Qiaquick gel extraction kit (Qiagen).
2.6. Sequencing
Reverse strand for fragments 1^4 was sequenced using the dye
primer cycle sequencing reaction M13 reverse kit (Applied Bioscien-
ces). Forward strands and the reverse strand for fragment 5 and the
1513 fragment were sequenced using the big dye terminator kit (Ap-
plied Biosciences). Template DNA and 3.2 pmol of the appropriate
primer were used in the sequencing reaction. Thermal cycling condi-
tions on a PTC225 thermal cycler (MJ Research) were 24 cycles of
1‡C/s to 96‡C, 96‡C for 10 s; 1‡C/s to 50‡C, 50‡C for 5 s; 1‡C/s to
60‡C, 60‡C for 4 min then 10 min at 15‡C. The sequencing reactions
were ethanol precipitated using sodium acetate and resuspended in
2 ul of a 5:1 mix of formamide (Sigma) to ABI loading dye (Applied
Biosystems). These were denatured at 95‡C for 2 min and kept on ice
before loading onto an ABI Prism 373. Analysis of the sequencing gel
was carried out using ABI Prism sequencing analysis software (Ap-
plied Biosystems) to produce sequencing traces. These were aligned
and analysed using the SeqMan programme of the Lasergene package
(DNAstar).
3. Results
3.1. ATP response phenotype of the cell donors
The ATP response phenotype of 7-day cultured monocyte-
derived macrophages isolated from nine cell donors utilised in
this study were screened for their reactions to stimulation with
3 mM ATP+/3IFNQ (100 IU/ml) for cell lysis, and P2X7
surface expression. Both the 51Cr release assay (Fig. 1), and
the £ow cytometry results (Fig. 2) identi¢ed and con¢rmed
that donors 2, 3 and 9 exhibited a low or non-ATP responder
phenotype, donors 4, 5, and 8 exhibited a high ATP responder
phenotype and donors 1, 6 and 7 exhibited an IFNQ-inducible
phenotype.
3.2. Sequencing of the P2RX7 promoter region
Genomic DNA was isolated from the blood of the nine
healthy cell donors. The promoter region 2 kb upstream of
P2RX7 exon 1 was then sequenced from each of three low
ATP responders (donors 2, 3 and 9), the three IFNQ-inducible
 
Fig. 1. Comparison of the cytotoxic ATP response phenotype of
7-day cultured monocyte-derived macrophages isolated from three
high (donors 4, 5 and 8), three low (donors 2, 3 and 9) and three
IFNQ-inducible responders (donors 1, 6, and 7) as assessed within a
51Cr release cytotoxicity assay in the presence or absence of IFNQ
(100 IU/ml).
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responders (donors 1, 6, and 7) and the three high responders
(donors 4, 5 and 8). Their nucleotide sequences were then
compared. Five SNPs were observed in both strands of the
putative 2-kb P2RX7 promoter region within the nine donors
examined (see Fig. 3). These were designated as follows:
3.2.1. 3298 polymorphism. On aligning the promoter se-
quence of the nine cell donors an A/G polymorphism was
observed at position 3298 (Fig. 3a). Of the three low respond-
ers examined, donor 9 had an AA genotype and donors 2 and
3 exhibited GG genotypes. Of the three high responders ex-
amined, donor 8 had a GG genotype and donors 4 and 5 had
A/G heterozygous genotypes. Of the three IFNQ-inducible re-
sponders examined, donor 6 had an A/G heterozygous geno-
type and donors 1 and 7 had a GG genotype. The AA geno-
type in donor 9 was therefore unique amongst the DNA
samples examined.
3.2.2. 3762 polymorphism. A T/C polymorphism was ob-
served at position 3762 (Fig. 3b). Of the three low respond-
ers, donor 9 was again unique within these samples in having
a TT genotype while donor 2 had a T/C genotype and donor 3
had a CC genotype. All three high responder donors 4, 5 and
8 had a TC genotype while of the three IFNQ-inducible re-
sponders, donors 1 and 6 also exhibited a heterozygous T/C
genotype and donor 7 a CC genotype.
3.2.3. 3838 polymorphism. A C/A polymorphism was ob-
served at position 3838 (Fig. 3c). The low responding donors
were again genotypically di¡erent, with donor 9 exhibiting an
AA genotype whereas donors 2 and 3 had a CC genotype.
This latter genotype was also observed in donors 1, 4, 6, 7 and
8. The exception was the high responder donor 5, who exhib-
ited a heterozygous AC genotype.
3.2.4. 31140 polymorphism. A T/C polymorphism was
observed at position 31140 (Fig. 3d). The genotype of the
low responder donor 9, was again distinct having a TT geno-
type while donors 2 and 3 were both CC genotypes. This
genotype was also observed in the two high responder donors
4 and 8 and in the IFNQ-inducible responder donors 1, 6 and
7. Donor 5 was heterozygous at this site with a C/T genotype.
3.2.5. 31269 polymorphism. A T/G polymorphism was
observed at position 31269 (Fig. 3e). Donor 9 expressed a
GG genotype while the other two low responder donors 2 and
3 were both TT genotypes at this position. The latter genotype
was also expressed by the two high responder donors 4 and 8
while the remaining donors, donors 1, 5, 7, had a heterozy-
gous TG genotype.
Overall, none of the P2XR7 promoter SNPs identi¢ed seg-
regated completely with any speci¢c ATP response phenotype.
3.2.6. 1513 polymorphism. The P2RX7 gene from each of
the nine cell donors was also sequenced to screen for the
presence of the 1513 loss of function polymorphism as de-
scribed previously [5]. This A/C mutation, which causes an
amino acid change from glutamic acid to alanine, was found
to be polymorphic in the nine donors examined (Fig. 3f).
Donor 2 had a CC genotype, donors 1 and 3 were heterozy-
gous and donors 4, 5, 6, 7, 8 and 9 were homozygous for the
A allele. All three low responders exhibited di¡erent geno-
types, indicating that the 1513 SNPs did not segregate with
a non-ATP responsive phenotype as assessed in this study.
4. Discussion
Donor response heterogeneity to ATP was con¢rmed to be
positively associated with macrophage P2X7 expression sug-
gesting that response phenotype may be genetically regulated
by polymorphisms in the P2RX7 promoter.
DNA from nine healthy cell donors, exhibiting three di¡er-
ent ATP response phenotypes were then screened for poly-
morphisms in a 2-kb region upstream of P2RX7 exon 1 and
¢ve SNPs were subsequently identi¢ed in this putative pro-
moter region. However, none of the individual SNPs were
found to be consistently associated with a speci¢c donor
ATP response phenotype. A recently described P2RX7 func-
tional polymorphism (1513) was also screened for within the
DNA of the nine cell donors examined but this SNP was also
not associated with any of the three de¢ned ATP response
phenotypes.
Our failure to ¢nd an association between the various SNPs
identi¢ed in the P2RX7 promoter and donor ATP response
phenotype may be attributed to a number of factors. These
include the possibility that the 2-kb sequence upstream of
P2RX7 exon 1 was not the actual receptor promoter. This
hypothesis is supported by the fact that no characteristic pro-
moter site markers, such as TATA boxes, were identi¢ed in
this region. However, it may be that the promoter SNPs iden-
ti¢ed only subtly a¡ect P2X7 expression or alternatively, only
a¡ect it under certain physiological conditions that were not
reproduced in this study.
No common polymorphisms were identi¢ed within this pro-
moter sequence, with the exception of the genotypes from
Fig. 2. Flow cytometry results depicting representative P2X7 surface
staining pro¢les of 7-day cultured monocyte-derived macrophages
isolated from two high ATP responding donors (donors 4 and 5,
a and b), two IFNQ-inducible responder donors (donors 1 and 6,
c and d) and two low responder donors (donors 2 and 9, e and f).
The isotype control staining pattern is represented by the open his-
togram, and the speci¢c anti-P2X7 staining is represented as the
closed histogram.
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       -323                   -273
Consensus
          GAAAGGGGGGAAAAGGGAGAATTCTGAAAATGCCCATCCTCTGAACACCAT
Donor 1   ---------------------------------------------------
Donor 2   ---------------------------------------------------
Donor 3   ---------------------------------------------------
Donor 4   -------------------------R-------------------------
Donor 5   -------------------------R-------------------------
Donor 6   -------------------------R-------------------------
Donor 7   ---------------------------------------------------
Donor 8   ---------------------------------------------------
Donor 9   -------------------------A------------------------- 
 
         -787                                                      -737
Consensus
          TGGTGTCCCTCACTGAATAGGTCAACAAACCTAACTTTGTTGGACTGCCAC
Donor 1   -------------------------Y-------------------------
Donor 2   -------------------------Y-------------------------
Donor 3   ---------------------------------------------------
Donor 4   -------------------------Y-------------------------
Donor 5   -------------------------Y-------------------------
Donor 6   -------------------------Y-------------------------
Donor 7   ---------------------------------------------------
Donor 8   -------------------------Y-------------------------
Donor 9   ------------------------- T-------------------------
          -863                                               -813
Consensus
           ACTCCACTTTCCTCGGAATCCTATACTAAATTGCTGTTTTCCTTTGTTTGG
Donor 1    ---------------------------------------------------
Donor 2    ---------------------------------------------------
Donor 3    ---------------------------------------------------
Donor 4    ---------------------------------------------------
Donor 5    -------------------------M-------------------------
Donor 6    ---------------------------------------------------
Donor 7    ---------------------------------------------------
Donor 8    ---------------------------------------------------
Donor 9          -------------------------A-------------------------
          -1165                                                   -1115
Consensus
           TAAAATCAGAGACCTTCAGAAACTTCGCTGTTTGAAATTACATGACTAAGA
Donor 1    ---------------------------------------------------
Donor 2    ---------------------------------------------------
Donor 3    ---------------------------------------------------
Donor 4    ---------------------------------------------------
Donor 5    -------------------------Y-------------------------
Donor 6    ---------------------------------------------------
Donor 7    ---------------------------------------------------
Donor 8    ---------------------------------------------------
Donor 9    ------------------------- T-------------------------
 
         -1294                                                -1244
Consensus
          ACTTAGCAGGCTGGAATAACAGAAATGGATCAAGCCAGCTGTAAAGATAAC
Donor 1   -------------------------K-------------------------
Donor 2   ---------------------------------------------------
Donor 3   ---------------------------------------------------
Donor 4   ---------------------------------------------------
Donor 5   -------------------------K-------------------------
Donor 6   ---------------------------------------------------
Donor 7   -------------------------K-------------------------
Donor 8   ---------------------------------------------------
Donor 9   -------------------------G-------------------------
 
          1488                  1538
Consensus
          cctgagagccacaggtgcctggaggAgctgtgctgccggaaaaagccggg
Donor 1   -------------------------M------------------------
Donor 2   -------------------------C------------------------
Donor 3   -------------------------M------------------------
Donor 4   --------------------------------------------------
Donor 5   --------------------------------------------------
Donor 6   --------------------------------------------------
Donor 7   --------------------------------------------------
Donor 8   --------------------------------------------------
Donor 9   ------------------------- -------------------------
(a)
(b)
(c)
(d)
(e)
(f)
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donors 3 and 9. None appears to be associated with any of the
three de¢ned ATP response phenotypes (i.e. high, low and
IFNQ-inducible responders) within the nine donors examined.
However due to the small sample size, more individuals ex-
pressing the distinct genotypes of donors 3 and 9 need to be
identi¢ed and assessed to determine whether these are more
frequently associated with low expression of the P2X7 recep-
tor. This latter hypothesis would also suggest that it is the
overall genotype or a combination of alleles that a¡ects re-
ceptor expression rather than the in£uence of a single allele.
Support for a regulatory role for the promoter SNPs comes
from the fact that we have found a positive association be-
tween one of the promoter SNPs (3762) and susceptibility to
TB within a Gambian population [12]. Although no known
binding motifs were found at or around the 3762 SNP site, a
search through the transfac database [7,8] indicated that three
transcription factors CCAAT enhancer binding protein (C/
EBP) [9], GATA binding factor 1 (GATA-1) [10] and delta
crystalline enhancer binding protein EF-1 (NEF-1) [11] could
recognise a motif in this region. Indeed the 3762 SNP was
found to reside in this motif. We are currently characterising
this region and investigating the e¡ects of the 3762 and the
other promoter SNPs on P2X7 function by cloning their reg-
ulatory sequences into reporter plasmids and transfecting
them into both human and murine monocytic cell lines to
look for di¡erential transcript activity. It is hoped that this
approach will help to identify the regulatory mechanisms
underlying the heterogeneity in ATP responsiveness observed
within human populations.
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Fig. 3. Polymorphisms were identi¢ed in the putative promoter region of the P2RX7 at 3298 (a), 3762 (b), 3838 (c), 31140 (d), 31269 (e)
and the 1513 polymorphism of exon 13 of the P2RX7 (f) in three high responding donors (4, 5, 8), three inducible donors (1, 6, 7) and three
low responding donors (2, 3, 9). Key heterozygous alleles are represented using the IUB codes: R=A or G, Y=C or T, M=A or C, K=T or
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